As a response to increasing levels of resistance to antimalarial medicines, WHO recommends that all countries experiencing resistance to conventional monotherapies, such as chloroquine, amodiaquine or sulfadoxine–pyrimethamine, should use combination therapies, preferably those containing artemisinin derivatives (ACTs – artemisinin-based combination therapies) for falciparum malaria.
WHO currently recommends the following combination therapies (in alphabetical order)for chloroquine resistant malaria:

artemether/lumefantrine
artesunate plus amodiaquine (In areas where the cure rate of amodiaquine monotherapy is greater than 80%)
artesunate plus mefloquine (Insufficient safety data to recommend its use in Africa)
artesunate plus sulfadoxine/pyrimethamine (In areas where the cure rate of sulfadoxine/pyrimethamine is greater than 80%)